30-MAY-2023 6:11

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac PREV   389 0 Y 0 Pre-Registration 708 18 6 4 0 0
              708 18 6 4 0 0
 
        1 Y 1 Blinded drug 135 5 2 1 0 0
            2 Blinded drug 36 0 0 0 0 0
            3 Blinded drug 35 0 0 0 0 0
            4 Blinded drug 143 10 4 2 2 0
              349 15 6 3 2 0
 
S1007-Breast,Adj,N1,Endocrine+/-Chemo BREAST CCD 9400 3 Y 4 Specimen Submission for CBALR TM Substudy 173 15 4 3 0 0
              173 15 4 3 0 0
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol SURV   817 1 Y 0 Screening 313 24 8 7 2 1
              313 24 8 7 2 1
 
        2 Y 1 Carvedilol 67 11 3 3 1 0
            2 No prophylaxis 71 11 4 3 0 0
            3 Observation 155 0 0 0 0 0
              293 22 7 6 1 0
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition SXQOL   200 1 Y 1 Blinded Nutrition Drink 85 18 11 9 4 1
            2 Blinded Nutrition Drink 92 19 8 4 1 0
              177 37 19 13 5 1
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 1320 1 Y 0 Screening 429 95 50 29 7 1
              429 95 50 29 7 1
 
        2 Y 1 Control (Usual Care) 142 29 21 12 5 2
            2 Intervention (STMDDM) 139 27 15 8 2 0
              281 56 36 20 7 2
 
S1706-Breast, Inflammatory, RT +/- Olaparib BREAST SXQOL 300 1 Y 1 Olaparib + RT 64 16 10 5 0 0
            2 RT 67 11 9 2 0 0
              131 27 19 7 0 0
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 686 127 61 40 12 3
              686 127 61 40 12 3
 
        2 Y 1 Standard Systemic Therapy Only 245 48 26 16 7 2
            2 SST + Surgery/RT 242 43 25 14 4 0
              487 91 51 30 11 2
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab GU SXQOL 475 1 Y 0 Initial Registration 423 121 59 35 9 1
              423 121 59 35 9 1
 
        2 Y 1 Chemo + RT 199 59 25 14 3 0
            2 Chemo + RT + Atezolizumab 204 61 34 21 6 1
              403 120 59 35 9 1
 
S1823-GCT, Obs. Cohort, miRNA371 PREV   956 1 Y 1 Observation Arm 746 238 120 72 30 9
              746 238 120 72 30 9
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 74 26 17 6 4 0
            2 MRI brain surveillance 76 28 16 8 5 1
              150 54 33 14 9 1
 
S1904-Breast, Decision making for chemoprevention PREV   415 1 Y 1 Standard Education Materials 127 48 25 12 3 0
            2 Support Tools + Standard Education Materials 159 70 31 15 4 0
              286 118 56 27 7 0
 
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship CCD   536 1 Y 1 Financial Navigation 41 28 18 8 2 0
            2 Control 42 27 19 9 3 1
              83 55 37 17 5 1
 
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo LUNG SXQOL 480 1 Y 1 Atezolizumab and SBRT 107 55 33 16 4 1
            2 SBRT 101 51 25 13 2 0
              208 106 58 29 6 1
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 30 14 4 4 3 0
            2 R-miniCHOP 26 11 4 4 1 0
              56 25 8 8 4 0
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 24 15 9 3 1 0
            2 Early V-O 44 28 15 8 3 1
              68 43 24 11 4 1
 
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed SXQOL   540 1 Y 1 Active Symptom Monitoring + Patient Education 4 4 4 4 1 0
            2 Patient Education 3 3 3 3 1 0
              7 7 7 7 2 0
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   2062 1 Y 1 Observation Arm 1063 798 511 290 93 15
              1063 798 511 290 93 15
 
S2108CD-Genomic Tumor Board vs Usual Practice CCD   1182 1 Y 1 Usual Practice 196 196 194 142 44 4
            2 EGTB Intervention 161 161 157 104 41 8
              357 357 351 246 85 12
 
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   777 1 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   25 16 9 5 1 0
              25 16 9 5 1 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   25 8 4 2 0 0
              25 8 4 2 0 0
 
        1 E   20 5 2 2 0 0
              20 5 2 2 0 0
 
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo GU SXQOL   1 E   107 19 8 4 1 0
              107 19 8 4 1 0
 
        2 E   72 14 6 4 1 0
              72 14 6 4 1 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   58 25 10 8 1 0
              58 25 10 8 1 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI GI SXQOL   1 E   23 8 4 3 3 1
              23 8 4 3 3 1
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   24 12 6 3 0 0
              24 12 6 3 0 0
 
        1 E   18 11 6 3 0 0
              18 11 6 3 0 0
 
        2 E   8 6 1 1 1 0
              8 6 1 1 1 0
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   16 8 6 3 2 1
              16 8 6 3 2 1
 
        2 E   16 7 5 3 3 1
              16 7 5 3 3 1
 
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction SXQOL OTHER   1 E   3 3 3 1 0 0
              3 3 3 1 0 0
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL   1 E   6 1 1 1 0 0
              6 1 1 1 0 0
 
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx GU SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST LUNG SXQOL   1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo GI SXQOL   1 E   23 6 4 3 1 0
              23 6 4 3 1 0
 
        2 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL   1 E   9 3 3 3 0 0
              9 3 3 3 0 0
 
A031902-Pros, Adv, Enzalutamide + Rucaparib GU SXQOL   0 E   5 1 1 0 0 0
              5 1 1 0 0 0
 
        1 E   5 1 1 0 0 0
              5 1 1 0 0 0
 
A032001-Blad, Met, Cabo +/- Avelumab after Chemo GU SXQOL   1 E   7 7 6 4 2 0
              7 7 6 4 2 0
 
A082002-Lung, Adv, Systemic Tx +/- SBRT LUNG SXQOL   1 E   3 3 2 1 0 0
              3 3 2 1 0 0
 
A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo MELAN SXQOL   0 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
        1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
A171901-NSCLC, > 70 Years Old, Pembro +/- Chemo LUNG SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   39 3 0 0 0 0
              39 3 0 0 0 0
 
A212102-Blind Ref Set for Multicancer Early Detection PREV     1 E   35 35 34 7 3 0
              35 35 34 7 3 0
 
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN SXQOL     1 E   8 3 1 1 0 0
              8 3 1 1 0 0
 
        2 E   6 1 0 0 0 0
              6 1 0 0 0 0
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
A231901C-Breast, Shared Decision Engagement System CCD SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
EA2182-Anal, Erly, DECREASE GI SXQOL   0 E   7 6 3 2 1 0
              7 6 3 2 1 0
 
        1 E   8 7 4 3 1 0
              8 7 4 3 1 0
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   12 5 3 0 0 0
              12 5 3 0 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   10 3 2 0 0 0
              10 3 2 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8183-Pros, Dbl Blind Andro Dep + Daro vs Placebo GU SXQOL   0 E   12 5 1 0 0 0
              12 5 1 0 0 0
 
        1 E   4 1 1 0 0 0
              4 1 1 0 0 0
 
EA8184-Pros, Dbl Blind GTC vs Placebo PREV SXQOL   0 E   3 3 1 1 0 0
              3 3 1 1 0 0
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8212-Blad, NMIBC, BRIDGE GU SXQOL   1 E   22 22 22 18 7 2
              22 22 22 18 7 2
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   49 12 7 5 2 2
              49 12 7 5 2 2
 
        1 E   22 3 1 1 0 0
              22 3 1 1 0 0
 
EAQ202-Improving AYA PROs in EA Trials SXQOL     1 E   43 16 1 0 0 0
              43 16 1 0 0 0
 
NHLBIMDS-LEUK, National MDS Study CCD     1 E   207 44 23 11 0 0
              207 44 23 11 0 0
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN007-Brain, New Dx, Ipi + Nivo vs Temozomide OTHER SXQOL   1 E   8 0 0 0 0 0
              8 0 0 0 0 0
 
        2 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
NRGBN011-Brain, Lomustine + Temo vs Temo OTHER SXQOL   1 E   5 5 2 1 0 0
              5 5 2 1 0 0
 
        2 E   2 2 1 0 0 0
              2 2 1 0 0 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   3 3 1 0 0 0
              3 3 1 0 0 0
 
        2 E   3 3 1 0 0 0
              3 3 1 0 0 0
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   6 4 1 1 0 0
              6 4 1 1 0 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 0 0 0 0 0
              15 0 0 0 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   18 17 7 5 1 0
              18 17 7 5 1 0
 
        2 E   16 15 7 3 1 0
              16 15 7 3 1 0
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   14 11 4 1 1 0
              14 11 4 1 1 0
 
        2 E   13 10 5 2 1 0
              13 10 5 2 1 0
 
NRGHN001-Nasopharyngeal , Indiviual Tx EBV OTHER SXQOL   1 E   9 0 0 0 0 0
              9 0 0 0 0 0
 
        2 E   8 0 0 0 0 0
              8 0 0 0 0 0
 
        3 E   7 0 0 0 0 0
              7 0 0 0 0 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL   1 E   7 1 0 0 0 0
              7 1 0 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        2 E   2 1 1 1 0 0
              2 1 1 1 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   6 4 3 3 1 0
              6 4 3 3 1 0
 
NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo LUNG SXQOL   1 E   13 0 0 0 0 0
              13 0 0 0 0 0
 
NRGLU006-Meso, Stg I-IIIA, Pleurectomy +/- Adj RT LUNG SXQOL   1 E   2 2 0 0 0 0
              2 2 0 0 0 0
 
        2 E   2 2 1 1 0 0
              2 2 1 1 0 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   6 1 1 1 0 0
              6 1 1 1 0 0
 
        2 E   5 1 1 1 0 0
              5 1 1 1 0 0
 
R1308-Lung, Stg II/III, Photon vs Proton Chemo RT LUNG SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 

30-MAY-2023 6:11

Cancer Coltrol Open Studies with No Registrations

Study Admin CCAdmin Registration/Phase Open Date
S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   1 Registration 16-Mar-23
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL 2 Late Randomization Callback 08-May-17
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 2 Randomization2 08-Sep-17
EA8184 Pros, Dbl Blind GTC vs Placebo PREV SXQOL 1 Randomization 20-May-21